Buy AOD9604 10mg

AOD9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177–191 of the C-terminus of human growth hormone (hGH), with an added N-terminal tyrosine for stabilisation. Unlike intact growth hormone, which exerts widespread anabolic, diabetogenic, and proliferative effects through the GH receptor (GHR) and downstream IGF-1 production, AOD9604 was designed to isolate the fat-metabolising activity of hGH without the insulin-antagonising and growth-promoting properties of the full molecule. The key discovery enabling this separation was the identification of the hGH 177–191 region as the primary sequence responsible for GH's lipolytic effect in adipose tissue, an activity mechanistically distinct from the anabolic signalling mediated by the GH receptor's N-terminal binding domains. At the receptor level, AOD9604 does not bind the classical GH receptor or stimulate IGF-1 production, which means it lacks the hyperglycaemic, proliferative, and fluid-retention side effects associated with exogenous GH administration. Instead, AOD9604 interacts with a beta-adrenergic-like receptor on adipocyte membranes—the precise identity of which remains an active area of investigation—activating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP). Elevated adipocyte cAMP activates protein kinase A (PKA), which phosphorylates two critical lipolytic effectors: hormone-sensitive lipase (HSL) at Ser563 and Ser660 (activating it), and perilipin-1 at Ser517 (releasing it from its protective role on the lipid droplet surface). Together, phosphorylated HSL and freed perilipin-1 enable the hydrolysis of stored triglycerides into diacylglycerol, monoacylglycerol, and ultimately glycerol and free fatty acids, which are released into the circulation for oxidation by peripheral tissues. AOD9604 also demonstrates the ability to stimulate adipocyte differentiation modulation—specifically, it appears to suppress preadipocyte differentiation into mature adipocytes by downregulating adipogenic transcription factors including PPAR-gamma and C/EBP-alpha, potentially limiting the expansion of adipose tissue mass at the level of adipogenesis rather than solely at the level of triglyceride mobilisation. This anti-adipogenic effect has been observed in both in vitro adipocyte culture models and in preclinical in vivo studies, suggesting a dual mode of action: acute lipolytic mobilisation of existing fat stores and chronic suppression of new adipocyte formation. The metabolic specificity of AOD9604 relative to full-length GH is its defining clinical advantage. Intact GH at pharmacological doses causes insulin resistance through hepatic and peripheral GHR-mediated upregulation of p85-alpha regulatory subunit expression in the PI3K insulin signalling pathway, effectively blocking insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue. AOD9604 lacks this insulin-antagonising activity entirely—glucose tolerance testing in human subjects showed no adverse effects on fasting or postprandial glucose, making it appropriate for metabolic research contexts where glucose homeostasis preservation is a primary concern. The compound's oral bioavailability—demonstrated in some preclinical studies—represents an additional potential advantage over injectable GH fragments, though subcutaneous administration remains the most studied route.

The 10 mg AOD9604 vial is appropriate for researchers investigating the GH-fragment lipolytic mechanism either as a standalone fat-loss intervention or as a complement to GLP-1-class protocols. Unlike GLP-1 receptor agonists, AOD9604's mechanism is primarily peripheral and lipolytic—it directly mobilises stored triglycerides from adipose tissue via the cAMP/PKA/HSL pathway rather than operating through central appetite suppression. This mechanistic distinction makes it an interesting research subject for protocols investigating additive effects of concurrent central satiety suppression (via GLP-1 agonism) and peripheral fat mobilisation (via AOD9604). Protocol design for AOD9604 research typically involves subcutaneous doses in the 200–500 mcg per injection range, administered daily or multiple times per week. At 200 mcg per day, a 10 mg vial provides approximately 50 doses—sufficient for a 7-week daily protocol or up to 14 weeks at 3 injections per week. The modest absolute dose size makes accurate measurement with insulin syringes critical, and reconstituting the 10 mg vial into 10 mL bacteriostatic water to achieve a 1 mg/mL working concentration simplifies dose measurement and reduces measurement error. From a quality verification standpoint, AOD9604's relatively short amino-acid sequence (16 residues) makes purity verification more straightforward than for longer peptides. HPLC purity above 98% and mass spectrometry confirmation of the correct molecular weight (approximately 1,815 Da) are the primary authenticity markers. Because AOD9604 does not activate the GH receptor or stimulate IGF-1 production, researchers interested in dissecting the fat-loss contribution of the GH axis without the confounding systemic effects of full-length GH will find the 10 mg vial provides a practical experimental quantity.

AOD9604 occupies a mechanistically unique niche in the fat-loss peptide landscape. Unlike GLP-1 receptor agonists—which primarily achieve fat loss through central appetite suppression and the secondary caloric deficit this creates—AOD9604 acts directly on adipocytes to stimulate triglyceride hydrolysis. This distinction makes it potentially complementary to, rather than competitive with, GLP-1-class agents. Research combining AOD9604 with semaglutide or tirzepatide explores the additive hypothesis: if GLP-1R agonism creates the caloric deficit that makes fat mobilisation thermodynamically favourable, and AOD9604 directly stimulates the lipolytic machinery, the combination could theoretically produce fat loss exceeding either agent alone. Against peptides like 5-Amino-1MQ—which operates at the level of preadipocyte differentiation suppression via NNMT inhibition—AOD9604 targets mature adipocyte triglyceride mobilisation rather than upstream adipogenesis. These are complementary mechanisms operating at different points in the adipocyte lifecycle. In absolute weight-loss terms, AOD9604's clinical trial data showed more modest outcomes than GLP-1 receptor agonists, reflecting the fact that peripheral lipolytic stimulation without concurrent appetite suppression does not reliably sustain the caloric deficit needed for continuous fat mass reduction. Its greatest research value lies in mechanistic studies, body-composition-specific protocols, or combination investigations rather than as a standalone weight-management intervention.